Your browser doesn't support javascript.
loading
Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study.
Kou, Kou; Cameron, Jessica; Youl, Philippa; Pyke, Chris; Chambers, Suzanne; Dunn, Jeff; Aitken, Joanne F; Baade, Peter D.
Afiliación
  • Kou K; Cancer Council Queensland, Spring Hill, PO Box 201, Brisbane, QLD, 4001, Australia.
  • Cameron J; Cancer Council Queensland, Spring Hill, PO Box 201, Brisbane, QLD, 4001, Australia.
  • Youl P; School of Mathematical Sciences, Queensland University of Technology, Brisbane, Australia.
  • Pyke C; Cancer Alliance Queensland, Metro South Hospital and Health Service, Woolloongabba, Australia.
  • Chambers S; Mater Hospitals South Brisbane, Brisbane, Australia.
  • Dunn J; Faculty of Health, University of Technology Sydney, Sydney, Australia.
  • Aitken JF; Prostate Cancer Foundation of Australia, Sydney, Australia.
  • Baade PD; Cancer Council Queensland, Spring Hill, PO Box 201, Brisbane, QLD, 4001, Australia.
Breast Cancer ; 30(3): 466-477, 2023 May.
Article en En | MEDLINE | ID: mdl-36809492
BACKGROUND: Interval breast cancers (BC) are those diagnosed within 24 months of a negative mammogram. This study estimates the odds of being diagnosed with high-severity BC among screen-detected, interval, and other symptom-detected BC (no screening history within 2 years); and explores factors associated with being diagnosed with interval BC. METHODS: Telephone interviews and self-administered questionnaires were conducted among women (n = 3,326) diagnosed with BC in 2010-2013 in Queensland. Respondents were categorised into screen-detected, interval, and other symptom-detected BCs. Data were analysed using logistic regressions with multiple imputation. RESULTS: Compared with screen-detected BC, interval BC had higher odds of late-stage (OR = 3.50, 2.9-4.3), high-grade (OR = 2.36, 1.9-2.9) and triple-negative cancers (OR = 2.55, 1.9-3.5). Compared with other symptom-detected BC, interval BC had lower odds of late stage (OR = 0.75, 0.6-0.9), but higher odds of triple-negative cancers (OR = 1.68, 1.2-2.3). Among women who had a negative mammogram (n = 2,145), 69.8% were diagnosed at their next mammogram, while 30.2% were diagnosed with an interval cancer. Those with an interval cancer were more likely to have healthy weight (OR = 1.37, 1.1-1.7), received hormone replacement therapy (2-10 years: OR = 1.33, 1.0-1.7; > 10 years: OR = 1.55, 1.1-2.2), conducted monthly breast self-examinations (BSE) (OR = 1.66, 1.2-2.3) and had previous mammogram in a public facility (OR = 1.52, 1.2-2.0). CONCLUSION: These results highlight the benefits of screening even among those with an interval cancer. Women-conducted BSE were more likely to have interval BC which may reflect their increased ability to notice symptoms between screening intervals.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans País/Región como asunto: Oceania Idioma: En Revista: Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans País/Región como asunto: Oceania Idioma: En Revista: Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Japón